These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30067880)

  • 1. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy.
    Chinn Z; Stoler MH; Mills AM
    Histopathology; 2019 Jan; 74(2):256-268. PubMed ID: 30067880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
    Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
    Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
    Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
    Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
    Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
    Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
    Venancio PA; Consolaro MEL; Derchain SF; Boccardo E; Villa LL; Maria-Engler SS; Campa A; Discacciati MG
    Cancer Cytopathol; 2019 Sep; 127(9):586-597. PubMed ID: 31412167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
    Hacking S; Chavarria H; Jin C; Perry A; Nasim M
    Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fascin and cyclin D1 immunoreactivity in non-neoplastic vulvar squamous epithelium, vulvar intraepithelial neoplasia and invasive squamous carcinoma: correlation with Ki67 and p16 protein expression.
    Stewart CJ; Crook ML
    J Clin Pathol; 2014 Apr; 67(4):319-25. PubMed ID: 24218024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression in HPV-associated Versus HPV-independent Invasive Vulvar Squamous Cell Carcinoma.
    Bui CM; Medeiros F; Azimpouran M; Venturina M; Balzer B
    Int J Gynecol Pathol; 2024 Jul; 43(4):405-413. PubMed ID: 38303111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
    Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
    Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
    Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
    Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
    Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
    JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
    Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
    Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
    Mills A; Zadeh S; Sloan E; Chinn Z; Modesitt SC; Ring KL
    Mod Pathol; 2018 Aug; 31(8):1282-1290. PubMed ID: 29559741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-G, HLA-E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma.
    Boujelbene N; Ben Yahia H; Babay W; Gadria S; Zemni I; Azaiez H; Dhouioui S; Zidi N; Mchiri R; Mrad K; Ouzari HI; Charfi L; Zidi I
    HLA; 2019 Jul; 94(1):11-24. PubMed ID: 30907063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Dill EA; Dillon PM; Bullock TN; Mills AM
    Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
    Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic study of thin vulvar squamous cell carcinomas and associated cutaneous lesions: a correlative study of 48 tumors in 44 patients with analysis of adjacent vulvar intraepithelial neoplasia types and lichen sclerosus.
    Chiesa-Vottero A; Dvoretsky PM; Hart WR
    Am J Surg Pathol; 2006 Mar; 30(3):310-8. PubMed ID: 16538050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
    Volaric A; Gentzler R; Hall R; Mehaffey JH; Stelow EB; Bullock TN; Martin LW; Mills AM
    Am J Surg Pathol; 2018 Sep; 42(9):1216-1223. PubMed ID: 29901571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.